BeOne Medicines (ONC) Q2 2026 earnings review
Massive Operating Leverage Unlocked, But H2 Guidance Implies a Spending Ramp
BeOne delivered a phenomenal Q2, driven by BRUKINSA's relentless global expansion. Revenue grew 30% YoY to $1.7 billion, and gross margins touched 90%. The real story is the bottom line: GAAP Operating Income exploded 270% to $325M, showcasing the structural operating leverage of the business. Management confidently raised the FY26 revenue guidance by $300M (at the midpoint). However, doing the math on the updated full-year operating income guidance reveals a hidden deceleration: implied H2 operating income drops significantly below Q2 levels, suggesting management is either heavily sandbagging or preparing for a massive late-stage R&D spending spree.
🐂 Bull Case
BRUKINSA continues to dominate, growing 31% YoY to $1.2B globally. It is single-handedly pulling gross margins up to 90% and generating massive cash flow ($435M FCF in Q2).
The 'Heme Triple Play' is materializing. BEQALZI (sonrotoclax) just secured FDA accelerated approval for R/R MCL, securing BeOne's grip on hematology beyond BRUKINSA.
🐻 Bear Case
Despite a massive Q2 beat, the raised FY26 GAAP operating income guidance of $1.0B-$1.1B implies average quarterly operating income will plummet from $325M in Q2 to ~$238M in Q3 and Q4.
BRUKINSA accounts for 71% of total product sales. Meanwhile, TEVIMBRA is severely lagging company averages with only 18% YoY growth, exposing vulnerabilities in the PD-1 space.
⚖️ Verdict: 🟢
Bullish. The cash generation and gross margin profile are elite. While the implied H2 margin compression requires scrutiny, the top-line momentum from BRUKINSA and successful regulatory execution on the broader pipeline justify the aggressive growth narrative.
Key Themes
BRUKINSA is the Ultimate Profit Engine
BRUKINSA sales accelerated to $1.2 billion globally (+31% YoY). The US market contributed $893 million (+31%). The high-margin nature of this drug is the sole reason BeOne's gross margin expanded from 87% to 90%. As long as this drug maintains its best-in-class BTK inhibitor status, it will fund the entire enterprise's R&D ambitions.
The Implied H2 Margin Deceleration
A major contradiction to the 'operating leverage' narrative lies in the guidance. H1 GAAP operating income reached $575M. The full-year guidance was raised to $1.0B-$1.1B. At the midpoint ($1.05B), this leaves only $475M in operating income for H2, or roughly $238M per quarter. This is a severe deceleration from the $325M generated in Q2, indicating either excessive conservatism or a massive incoming ramp in R&D and SG&A expenses to support late-stage trials.
Hematology Franchise Diversification (BEQALZI)
The FDA's accelerated approval of BEQALZI (sonrotoclax) for R/R MCL is a critical milestone. It validates BeOne's strategy to build a 'Heme Triple Play' (BRUKINSA + BEQALZI + BTK CDAC). This approval transitions sonrotoclax from an R&D expense to a commercial asset, reducing the long-term concentration risk currently carried by BRUKINSA.
TEVIMBRA Growth is Lagging
TEVIMBRA global sales grew 18% YoY to $229 million. While acceptable in isolation, this significantly trails the company's overall revenue growth of 30%. The PD-1 space remains hyper-competitive, and TEVIMBRA's decelerating relative momentum suggests it will not be the primary growth driver management once hoped for.
Macro Onshoring: Supply Chain De-risking
In a preemptive move against macro geopolitical and tariff risks, BeOne announced a $300 million expansion of its Princeton West Innovation Campus in New Jersey. Adding internal small molecule manufacturing capabilities directly inside the U.S. insulates its most critical supply chains (specifically BRUKINSA) from potential future trade disputes.
Solid Tumor Pipeline Progress (ZIIHERA & Gastric Cancer)
The solid tumor pipeline is finally yielding tangible clinical validation. Full Phase 3 results for ZIIHERA (zanidatamab) in HER2+ gastroesophageal adenocarcinoma were published in the NEJM. Concurrently, TEVIMBRA secured Japanese regulatory approval for first-line gastric cancer. These developments open up substantial new total addressable markets outside of hematology.
Other KPIs
Accelerating significantly. Up 98% YoY from $220M in 25Q2. The company is now a cash-generating machine, adding to a balance sheet that currently holds $5.28 billion in cash and equivalents. This allows the business to self-fund all R&D without dilutive financing.
Growing but stable as a percentage of revenue. Increased 17% YoY on a GAAP basis, driven by advancing early clinical programs into late-stage trials. Despite the large absolute dollar increase, R&D growth (+17%) was significantly outpaced by revenue growth (+30%), which is exactly what investors want to see.
Reversing prior stagnation. Global sales grew 25% YoY. However, management previously highlighted upcoming XGEVA biosimilar competition (filed in April), making this segment highly vulnerable to sudden deceleration in late 2026.
Guidance
Accelerating on an absolute basis. Management raised the previous guidance of $6.3B-$6.5B by $300M at the midpoint. This implies approximately 25% YoY growth compared to FY25's $5.34B. Given H1 revenue was $3.2B, it implies H2 revenue of ~$3.5B, signaling stable to slightly accelerating sequential momentum.
Decelerating sequentially but up massively YoY. Upgraded from the prior $750M-$850M range. While this represents a ~135% YoY increase from FY25's $447M, it implies H2 operating income will be significantly lower than H1 ($475M vs $575M), suggesting heavy upcoming investments.
Raised slightly from the prior $4.7B-$4.9B. With H1 GAAP expenses at $2.3B, this explicitly confirms management intends to spend $2.5B-$2.7B in H2. This fully explains the implied drop in sequential H2 operating income.
Key Questions
H2 Margin Deceleration Dynamics
Your updated full-year guidance implies a sequential drop in operating income for H2 compared to H1, despite rising revenue. Are you sandbagging, or are there specific, massive Phase 3 clinical trial initiations pulling operating expenses structurally higher in Q3 and Q4?
Defending TEVIMBRA
TEVIMBRA grew 18% YoY, significantly lagging the 30% growth of the overall business and the 31% growth of BRUKINSA. What specific commercial strategies are being implemented to accelerate TEVIMBRA, or should we expect it to permanently lag the company average?
Capital Allocation Tipping Point
With $5.28 billion in cash and $435 million of free cash flow generated this quarter alone, the balance sheet is highly capitalized. When does the conversation shift from pure pipeline funding toward aggressive share buybacks or larger-scale M&A?